IDEXX Laboratories, Inc. (IDXX) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $584.05. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of IDXX = $394.53 (-32.4% from the current price, the stock appears overvalued). Analyst consensus target is IDXX = $784 (+34.3% upside).
Valuation: IDXX trades at a trailing Price-to-Earnings (P/E) of 44.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.31.
Financials: revenue is $4.3B, +8.5%/yr average growth. Net income is $1.1B, growing at +16.3%/yr. Net profit margin is 24.6% (strong). Gross margin is 61.8% (+2.3 pp trend).
Balance sheet: total debt is $1.1B against $1.6B equity (Debt-to-Equity (D/E) ratio 0.67, moderate). Current ratio is 1.17 (adequate). Debt-to-assets is 32.1%. Total assets: $3.4B.
Analyst outlook: 13 / 22 analysts rate IDXX as buy (59%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 31/100 (Fail), Growth 73/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 80/100 (Pass), Future 64/100 (Pass), Income 85/100 (Pass).
